510(k) K062028
K062028 is an FDA 510(k) premarket notification submitted by Celera Diagnostics for the device "CYSTIC FIBROSIS GENOTYPING ASSAY, MODEL 6L20-01". The FDA issued a decision of Substantially Equivalent on September 7, 2007. The device falls under product code NUA (System, Cystic Fibrosis Transmembrane Conductance Regulator, Gene Mutation Detection), a Class II device regulated under 21 CFR 866.5900.
Clearance Details
- Decision
- SESE (Substantially Equivalent)
- Decision Date
- September 7, 2007
- Date Received
- July 18, 2006
- Clearance Type
- Traditional
- Expedited Review
- No
- Third Party Review
- No
Device Classification
- Device Name
- System, Cystic Fibrosis Transmembrane Conductance Regulator, Gene Mutation Detection
- Device Class
- Class II
- Regulation Number
- 866.5900
- Review Panel
- PA
- Submission Type
The cftr gene mutation detection system is a device used to simultaneously detect and identify a panel of mutations and variants in the cftr gene. It is intended as an aid in confirmatory diagnostic testing of individuals with suspected cystic fibrosis (cf), carrier identification, and newborn screening. This device is not intended for stand-alone diagnostic purposes, prenatal diagnostic, pre-implantation or population screening.